We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Trailing the pack

14 Aug 2018 By Lauren Silva Laughlin

The activist investor has backed away from his fight against the U.S. health insurer’s $52 bln deal to buy Express Scripts. On merit alone, his opposition was justified. But for activists, that is no longer enough to win. Shifting shareholder rosters have changed the game.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)